Transgene (Euronext Paris: TNG), a biotechnology company that specialises in virus-based immunotherapies for cancer treatment, reported on Monday that it has shared new data on TG4001, its therapeutic cancer vaccine.

This data was presented at the ASCO Annual Meeting and confirms TG4001's ability to induce immune responses against HPV16 antigens associated with anti-tumour response.

TG4001 is currently being evaluated in a Phase II clinical study in combination with avelumab for patients with HPV16-positive anogenital tumors. The study shows that TG4001 significantly increased immune responses against HPV antigens compared to avelumab alone. Notably, patients with a vaccine-induced immune response exhibited stable disease or complete tumour response. Transgene is preparing for a potentially registrational trial to further validate the benefits of TG4001.

Dr Alessandro Riva, Chairman and CEO of Transgene, expressed excitement about the data and its potential implications for patients with HPV-positive cancers. TG4001 has demonstrated good safety and promising efficacy results in previous studies, making it a strong candidate for combination therapies in HPV-mediated solid tumours.

Transgene's portfolio also includes therapeutic vaccines and oncolytic viruses for cancer treatment.